丹麦阿拉食品原料发布《2025中国特殊医学用途食品（特医食品）行业及消费者洞察白皮书》

Core Insights - Arla Foods Ingredients released the "Everything for Patients" white paper on the Chinese special medical purpose food (FSMP) industry and consumer insights at the 2025 Dairy Ingredients and Nutrition Science Seminar, providing a comprehensive review of the industry's development over the past decade [1][5]. Industry Overview - The white paper is based on quantitative research involving over 12,000 respondents across 12 countries and in-depth interviews with 40 patients and nutrition experts from four countries, offering systematic references for high-quality industry development [5]. - The Chinese FSMP market is projected to grow from approximately 164 billion yuan in 2024 to 240 billion yuan by 2030, with a compound annual growth rate (CAGR) of 6.58% [6]. - As of September 2025, 277 FSMP products have been approved in China, with 183 new products registered since 2023, surpassing the total from the previous six years [6]. Consumer Insights - The white paper highlights that patient adherence is influenced by communication with healthcare providers, product experience, and pricing, with about half of patients globally struggling to follow medical advice due to taste, tolerance, and economic burden [8][12]. - Approximately 60-80% of patients rely on healthcare professionals for product recommendations, and around 70% experience discomfort such as diarrhea or nausea during use, indicating taste and tolerance as core pain points [12]. Future Trends - The FSMP industry in China is transitioning from "nutritional support" to "precision nutritional intervention," focusing on localized solutions that align with the disease spectrum, metabolic characteristics, and dietary habits of the Chinese population [13]. - Digital technologies are reshaping innovation pathways in FSMP, with advancements such as 3D printing, wearable devices, AI algorithms, and nutrition apps supporting personalized nutrition management [14]. - Arla Foods Ingredients is introducing diverse raw material solutions targeting clinical scenarios like chronic kidney disease and type 2 diabetes, emphasizing protein innovation as a key industry breakthrough [14].